Shares of Clovis Oncology Inc. (NASDAQ: CLVS) catapulted about 120% by afternoon trade. The biopharmaceutical Company reported on Monday that its early stage clinical trials on a lung cancer treatment showed contraction in the size of tumor. The experimental treatment, dubbed as CO-1686, targets to cure non-small lung cancer (NSCLC) in patients with a transmutation in gene T790M.
Continue reading Major Movers on June 3; CLVS, TSRO, MNKD, CBRL, FFIV